Table 2 Circulatory and renal support during the study period
From: Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus
Day 1 | Day 3 | Day 7 | Day 10 | Day 14 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
ECMO (n = 17) | Non-ECMO (n = 18) | ECMO (n = 14) | Non-ECMO (n = 15) | ECMO (n = 14) | Non-ECMO (n = 15) | ECMO (n = 14) | Non-ECMO (n = 15) | ECMO (n = 14) | Non-ECMO (n = 14) | |
Use of norepinephrine n (%) | 5 (29.4%) | 12 (80%)* | 8 (57.1%) | 11 (73.3%) | 7 (50%) | 13 (86.7%) | 7 (50%) | 12 (80%) | 5 (35.7%) | 13 (92.9%)* |
Max. dose (µg kg−1 min−1) | 0.08 (0.16) | 0.13 (0.25) | 0.04 (0.55) | 0.15 (0.17)* | 0.04 (0.58) | 0.43 (0.69)* | 0.15 (0.30) | 0.06 (0.09) | 0.44 (0.58) | 0.5 (0.71) |
Use of dobutamine n (%) | 2 (11.8%) | 2 (11.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Max. dose (µg kg−1 min−1) | 1.5 (2.21) | 5.0 (8.66) | NA | NA | NA | NA | NA | NA | NA | NA |
Use of epinephrine n (%) | 0 (0%) | NA | 0 (0%) | NA | 0 (0%) | 1 (6.7%) | 1 (7.1%) | NA | 1 (5.9%) | NA |
Max. dose (µg kg−1 min−1) | NA | NA | NA | NA | NA | 1.1 (0.90) | 0.10 (0.14) | NA | 1.5 (0.00) | NA |
Use of CRRT n (%)a | 3 (17.6%) | 4 (22.2%) | 7 (50%) | 6 (40%) | 8 (57.1%) | 6 (46.7%) | 5 (35.7%) | 3 (20%) | 2 (14.3%) | 1 (7.10%) |